Cargando…
Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
BACKGROUND: As the efficacy of programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with chemotherapy in curing breast cancer is still controversial, this meta-analysis compares the efficacy and safety of PD-1/PD-L1 inhibitors combined with chemotherapy and chemotherapy...
Autores principales: | Qian, Da, Xu, Yuhao, Wu, Yihao, Qiu, Jie, Hong, Weimin, Meng, Xuli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344516/ https://www.ncbi.nlm.nih.gov/pubmed/37279392 http://dx.doi.org/10.1097/CM9.0000000000002631 |
Ejemplares similares
-
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis
por: Hu, Hao, et al.
Publicado: (2018) -
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical
trials
por: Zhao, Bin, et al.
Publicado: (2020) -
Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
por: Li, Huijuan, et al.
Publicado: (2023) -
The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017) -
PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)